NCT03915951 2025-11-17
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
Clinical Trials
9 trialsNCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT01894672 2024-07-16
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02631447 2024-06-07
SECOMBIT
Fondazione Melanoma Onlus
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT03693170 2024-02-02
ANCHOR-CRC
Pierre Fabre Medicament
Phase 2 Completed
NCT02834364 2023-11-24
GMMG-BIRMA
University of Heidelberg Medical Center
Phase 2 Completed